Rifampicin treatment of cutaneous leishmaniasis.
In a small-scale preliminary trial of oral rifampicin treatment was considered successful in six out of eight cutaneous leishmaniasis patients and probably effective in a seventh. The in vitro effect of rifampicin on leishmania organisms concerns inhibition of mitochondrial function or replication. The need for protozoological control in the assessment of treatment is stressed.